Condition: Advanced Solid Cancer · Metastatic Solid Cancer · Sponsor: Boehringer Ingelheim
This study is open to adults with advanced cancer. The purpose of this study is to find the highest dose of BI 3819026 that people with advanced cancer can tolerate when taken alone and together with ezabenlimab. BI 3819026 and ezabenlimab are study medicines that may fight cancer. Participants first receive one treatment of BI 3819026 alone, followed by treatment with a combination of BI 3819026 and ezabenlimab. Different doses of BI3819026 are given to small groups of participants, starting with the lowest dose. Treatment with the next higher dose of BI 3819026 starts only if the previous dose was tolerated. Each participant remains on the same dose of BI 3819026 throughout the study. Participants are in the study for up to 2 years as long as they can tolerate the treatment and their condition does not get worse. During this time, they visit the study site regularly. The doctors look at the occurrence of certain health problems. They also regularly take blood samples, image participants' tumours, and take note of any unwanted effects.
This description comes directly from the study's public registry record.
Boehringer Ingelheim · 1-800-243-0127 · clintriage.rdg@boehringer-ingelheim.com
Always discuss trial participation with your own doctor first.
| Yale Cancer Center | New Haven, Connecticut, United States | Not Yet Recruiting |
| Hackensack University Medical Center | Hackensack, New Jersey, United States | Not Yet Recruiting |
| New York University Langone Medical Center | New York, New York, United States | Not Yet Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| National Cancer Center Hospital East | Chiba, Kashiwa, Japan | Recruiting |
| National Cancer Center Hospital | Tokyo, Chuo-ku, Japan | Recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona, Spain | Recruiting |
| Clínica Universidad de Navarra | Pamplona, Spain | Recruiting |
| Hospital Clinico Universitario de Valencia | Valencia, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07607678